article · Clinical Infectious Diseases

Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis

Berend J. van Welzen
Cees van Nieuwkoop
Jan M. Prins
S.F.L. van Lelyveld
Gitte Van Twillert
Marc van der Valk
David M. Burger
Jet Gisolf
Suzanne E. Geerlings
G. ter Beest
Annemarie M. J. Wensing

202446 citationsOpen accessUniversity of the Witwatersrand

In plain language

The abstract on record is too brief for a reliable plain-language summary, so none has been generated.

Abstract

This is the first in-depth multiple case analysis of VF on LA CAB/RPV therapy in a real-world setting. Our observations stress the need to be aware for (evolving) risk factors and the yield of a comprehensive clinical, virological, and pharmacokinetic approach in case of failure.

Research topics

HIV/AIDS drug development and treatment
HIV Research and Treatment
Hepatitis C virus research

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1093/cid/ciae016

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.